OSE Immunotherapeutics Provides Regulatory Update on Tedopi,

Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today provides a regulatory update on the clinical development plan of Tedopi®, an immunotherapy activating

Related Keywords

Italy , Paris , France General , France , Spain , French , Dennis Riedl , Nicolas Poirier , Thomas Guillot , Florence Portejoie , Sylvie Berrebi , Nantes University Hospital , Linkedin , Twitter , Boehringer Ingelheim , French National Authority For Health , Drug Administration , International Media , European Medicines Agency , Veloxis Pharmaceuticals Inc , Us Food Drug Administration , Regulatory News , Chief Executive Officer , Typec Meeting , Role Functioning , French National Authority , Small Cell Lung Cancer , Non Small Cell Lung Cancer , Veloxis Pharmaceuticals , Universal Registration Document , Immunotherapeutics , Rovides , Egulatory , Update , Edopi , Dancer , Vaccine , Gate , Stage , Linical , Development , Young , After , Failure , Mmunotherapies ,